Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone + pirfenidone
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Topical, Inhalation, Intranasal, Ophthalmic
01
Overview
Triamcinolone + pirfenidone is a combination of two pharmaceutical agents. Triamcinolone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, used to treat various inflammatory and autoimmune conditions such as allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders (including multiple sclerosis), ophthalmic diseases, renal and respiratory diseases[3][5]. Pirfenidone is an antifibrotic small molecule approved for the treatment of idiopathic pulmonary fibrosis (IPF). It exerts its effects by reducing fibroblast proliferation and inhibiting the production of fibrogenic mediators such as transforming growth factor beta; it also has anti-inflammatory and antioxidant properties[1][2][6][8]. The combination may be considered in clinical or research settings where both anti-inflammatory and antifibrotic actions are desired.
- Brand names
- Esbriet (for pirfenidone)
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on triamcinolone + pirfenidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone + pirfenidone.